What does this research mean for the field?

TP53 alteration is the strongest independent adverse prognostic factor for overall survival in acute myeloid leukaemia patients after allogeneic haematopoietic cell transplantation, primarily driven by excess relapse, with distinct molecular subgroups showing varying survival outcomes. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the clinical outcomes of TP53-altered acute myeloid leukemia following allogeneic hematopoietic cell transplantation and characterize prognostic subgroups within this mutational profile.

September 6, 2026Bone Marrow TransplantationOpen Access

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

MRMartina Reuss TMThomas Meyer FIFlorian Ingelfinger

Discussion

Member takes

Overview

Retrospective cohort study reveals inferior survival driven by relapse in TP53-altered acute myeloid leukemia after stem cell transplant, highlighting distinct prognostic subgroups.

Key Points

To evaluate the clinical outcomes of TP53-altered acute myeloid leukemia following allogeneic hematopoietic cell transplantation and characterize prognostic subgroups within this mutational profile.
Conducted a single-center retrospective analysis of 61 consecutive TP53-altered acute myeloid leukemia patients undergoing first allogeneic hematopoietic cell transplantation compared with 636 TP53-wild-type controls between 2007 and 2025.
Performed hierarchical clustering analysis incorporating an additional seven patients from a second center (total N=68 TP53-altered) to identify distinct molecular subsets.
TP53-altered patients had significantly worse 5-year overall survival compared to wild-type controls (18% vs. 50%; median 379 vs. 1694 days; p < 0.001), primarily driven by higher 5-year relapse rates (55% vs. 33%; p < 0.001), while non-relapse mortality was similar (28.5% vs. 23%; p = 0.426).
Multivariable Cox regression confirmed TP53 alteration as the strongest independent predictor of inferior overall survival (HR 2.54, 95% CI 1.77–3.64; p < 0.001), persisting after adjustment for cytogenetic risk and Disease Risk Index.
Clustering analysis identified two distinct prognostic subgroups: a del(17p)-enriched cluster (n = 12) with a median overall survival of 5.7 months and a TP53 point mutation-enriched cluster (n = 56) with a median overall survival of 15.1 months.

Cite This Study

Reuss et al. (2026) studied this question.

synapsesocial.com/papers/6a9d1ec828139818eab21eee https://doi.org/10.1038/s41409-026-03029-2

View Full Paper

Ask AI

Bookmark

September 6, 2026Bone Marrow TransplantationOpen Access

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation

View Full Paper

Ask AI

Bookmark

Authors

MRMartina Reuss TMThomas Meyer FIFlorian Ingelfinger

Discussion

Member takes

Overview

Retrospective cohort study reveals inferior survival driven by relapse in TP53-altered acute myeloid leukemia after stem cell transplant, highlighting distinct prognostic subgroups.

Key Points

To evaluate the clinical outcomes of TP53-altered acute myeloid leukemia following allogeneic hematopoietic cell transplantation and characterize prognostic subgroups within this mutational profile.
Conducted a single-center retrospective analysis of 61 consecutive TP53-altered acute myeloid leukemia patients undergoing first allogeneic hematopoietic cell transplantation compared with 636 TP53-wild-type controls between 2007 and 2025.
Performed hierarchical clustering analysis incorporating an additional seven patients from a second center (total N=68 TP53-altered) to identify distinct molecular subsets.
TP53-altered patients had significantly worse 5-year overall survival compared to wild-type controls (18% vs. 50%; median 379 vs. 1694 days; p < 0.001), primarily driven by higher 5-year relapse rates (55% vs. 33%; p < 0.001), while non-relapse mortality was similar (28.5% vs. 23%; p = 0.426).
Multivariable Cox regression confirmed TP53 alteration as the strongest independent predictor of inferior overall survival (HR 2.54, 95% CI 1.77–3.64; p < 0.001), persisting after adjustment for cytogenetic risk and Disease Risk Index.
Clustering analysis identified two distinct prognostic subgroups: a del(17p)-enriched cluster (n = 12) with a median overall survival of 5.7 months and a TP53 point mutation-enriched cluster (n = 56) with a median overall survival of 15.1 months.

Cite This Study

Reuss et al. (2026) studied this question.

synapsesocial.com/papers/6a9d1ec828139818eab21eee https://doi.org/10.1038/s41409-026-03029-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark